Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib
Matteson E, Distler O, Distler J, Kuwana M, Pope J, Seibold J, James A, Schlenker-Herceg R, Rohr K, Flaherty K (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: WILEY
City/Town: HOBOKEN
Conference Proceedings Title: ARTHRITIS & RHEUMATOLOGY
Authors with CRIS profile
Involved external institutions
Nippon Medical School
Japan (JP)
Boehringer Ingelheim Pharma GmbH & Co. KG
Germany (DE)
Scleroderma Research Consultants LLC
United States (USA) (US)
University of Michigan
United States (USA) (US)
Universitätsspital Zürich (USZ)
Switzerland (CH)
Western University
Canada (CA)
Mayo Clinic
United States (USA) (US)
Japan (JP)
Boehringer Ingelheim Pharma GmbH & Co. KG
Germany (DE)
Scleroderma Research Consultants LLC
United States (USA) (US)
University of Michigan
United States (USA) (US)
Universitätsspital Zürich (USZ)
Switzerland (CH)
Western University
Canada (CA)
Mayo Clinic
United States (USA) (US)
How to cite
APA:
Matteson, E., Distler, O., Distler, J., Kuwana, M., Pope, J., Seibold, J.,... Flaherty, K. (2020). Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib. In ARTHRITIS & RHEUMATOLOGY. HOBOKEN: WILEY.
MLA:
Matteson, Eric, et al. "Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib." Proceedings of the ARTHRITIS & RHEUMATOLOGY HOBOKEN: WILEY, 2020.
BibTeX: Download